Kashyap Patel, MD
Clinical Neurophysiology · Statesboro, GANPI 1700947231
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,000 of the $199,387 with a category attached, or 70.7%. 57 manufacturers reported payments, led by AbbVie at 56.7% of the total. Reporting peaked in 2021 at $83,163 and has fallen 97.6% since, to $2,014 in 2025.
Across 1,202 payments — averaging $165.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$113K
- Biohaven Pharmaceutical Holding Company Ltd.$24K
- Biohaven Pharmaceuticals, Inc.$23K
- Impel Pharmaceuticals Inc.$14K
- Teva Pharmaceuticals USA, Inc.$8K
- Livanova USA, Inc.$2K
- plus $15K from 51 others
Across 1 payment — averaging $584.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$584
What the payments were for
- Consulting fees$23,24612%
- Speaking & faculty fees$141,00071%
- Travel & lodging$11,7246%
- Food & beverage$23,26712%
- Education$1490%
- Gifts$00%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$84,155
- NURTEC ODT$44,985
- QULIPTA$23,813
- BOTOX$14,291
- Trudhesa$13,575
- AJOVY$6,726
- VNS Therapy$1,703
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$246
- AUBAGIO$240
- DARZALEX$137
- BRIUMVI$125
- AUSTEDO$125
- Leqembi$124
- ZEPOSIA$123
- Mavenclad$120
- OCREVUS$118
- Austedo XR$107
- LifeVest$106
How this compares
Too few clinical neurophysiology providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 53 | $478,148 |
| Nurtec OdtRimegepant Sulfate | 200 | $382,660 |
| IngrezzaValbenazine Tosylate | 15 | $201,761 |
| UbrelvyUbrogepant | 104 | $180,426 |
| AustedoDeutetrabenazine | 24 | $167,941 |
| Plegridy PenPeginterferon Beta-1a | 17 | $145,239 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 148 | $118,031 |
| BotoxOnabotulinumtoxina | 74 | $98,661 |
| Emgality PenGalcanezumab-Gnlm | 124 | $90,039 |
| QuliptaAtogepant | 59 | $66,268 |
| Ajovy SyringeFremanezumab-Vfrm | 55 | $38,703 |
| ZtlidoLidocaine | 85 | $32,919 |
| VimpatLacosamide | 42 | $31,748 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $30,162 |
| ProvigilModafinil | 11 | $25,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $634 | $382,660200 claims |
| AbbVieUbrelvy, Botox, Qulipta | $113,075 | $345,355237 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $218 | $201,76115 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $8,435 | $167,94124 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $677 | $32,91985 claims |
| UCB, Inc.Vimpat | $942 | $31,74842 claims |
| Eisai Inc.Fycompa | $933 | $18,97815 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $252 | $15,75212 claims |
| SK Life Science, Inc.Xcopri | $670 | $12,20511 claims |
| Upsher-smith Laboratories LLCTopiramate | $85 | $2,032284 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Statesboro
- Michael RivnerMacon$300K
- Ashish KabirDalton$83K
- Joseph HormesMarietta$4K
- Sachin KedarAtlanta$3K
- Gregory EsperAtlanta$3K
- William RocheMacon$474
- Sara Ann Schleicher-DilksGainesville$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.